NAMPT

Data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies, that selectively kills cancer cells and is thousands-fold better tolerated by healthy cells than previous NAMPT inhibitors. First presentation showcasing Remedy Plan's unique, first-in-class mechanism of action that is optimized to preserve cellular metabolism in healthy cells, while inhibiting activity in malignant cells, through fractional and tunable inhibition of NAMPT. GAITHERSBURG, Md., Dec. 10, 2023 /PRNewswire/ -- Remedy Plan Therapeutics ("Remedy Plan"), a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, today announced new data to be shared during an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, California, December 9-12th. Remedy Plan will present data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies. RPT1G is a small molecule NAMPT inhibitor with a unique, first-in-class mechanism of action that is optimized to preserve the cellular metabolism in healthy cells, while inhibiting activity in malignant cells. This is achieved through hyperbolic inhibition of NAMPT that is fractional and highly tunable. Preclinical and animal studies revealed that RPT1G is efficacious in acute leukemia, lymphoma, and solid tumor models, selectively killing cancer cells. Importantly, RPT1G was thousands-fold better tolerated by healthy cells, without the severe on-target toxicities reported for other NAMPT inhibitors. "We are excited to introduce our clinical candidate RPT1G, a first-in-class NAMPT drug that shows efficacy without the severe on-target toxicities seen with other NAMPT inhibitors," said Greg Crimmins, Ph.D., CEO and Founder of Remedy Plan. "NAMPT dysregulation is responsible for more than 20 diseases, but efforts to target NAMPT to date have been hampered by on-target toxicities. Our groundbreaking mechanism of action has the potential to revolutionize the field of NAMPT inhibition, unlocking opportunities for treating hematological malignancies and solid tumors, as well as autoimmune and metabolic diseases." NAMPT is central to cancer metabolism and is up-regulated in many solid and hematological malignancies, making it a high-value oncology target. Based on the promising data presented at ASH, RPT1G will be advancing to the clinic in 2024. Abstract and Presentation details: Remedy Plan's CEO and Founder Greg Crimmins, Ph.D. will present the data on Sunday December 10th at 10:30AM PST in Grand Hall B of the Manchester Grand Hyatt San Diego, and all meeting participants are encouraged to attend either in person or online. A 1st-in-Class Small Molecule NAMPT Inhibitor as a Novel Therapeutic for Acute Lymphocytic Leukemia. Abstract #419, Oral Session: 605, Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias. The full abstract is available here. About Remedy Plan Therapeutics Remedy Plan is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for allosteric inhibition of NAMPT that is fractional and highly tunable. NAMPT is an enzyme that controls how cells use energy and is core to human biology and its dysregulation is responsible for over 20 diseases. Efforts to reduce NAMPT activity to date have resulted in unmanageable toxicities to healthy cells due to the essential role of NAMPT in healthy cell functioning and disease. Remedy Plan's groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. Remedy Plan is advancing a robust pipeline of tunable NAMPT inhibitors to address solid tumors, hematological malignancies, obesity, and autoimmune disorders. About RPT1G, a novel oncology therapeutic Remedy Plan's lead asset is RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies. RPT1G has a unique, first-in-class mechanism of action that is optimized to preserve the cellular metabolism in healthy cells, while inhibiting activity in malignant cells. With a favorable efficacy and tolerability profile in animals, RPT1G will be advancing to the clinic in 2024. For more information, please visit and follow Remedy Plan on social media: Contact: Parisa Moghaddam-Taaheri, [email protected] SOURCE Remedy Plan Therapeutics

GAITHERSBURG, MD / ACCESSWIRE / December 6, 2023 / Remedy Plan Therapeutics ("Remedy Plan"), a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, is pleased to announce the expansion of its leadership team with the appointment of Cassandra Choe-Juliak, M.D., M.S., as the acting Chief Medical Officer (CMO). Dr. Choe-Juliak has more than 17 years of experience in biopharma, most recently as the Chief Medical Officer at Flame Biosciences and at Tiga Therapeutics. She has previously held leadership positions in clinical development at Affimed and Karyopharm Therapeutics. At Karyopharm Therapeutics, she helped lead the clinical development strategy for Selinexor, a first-in-class XPO1 inhibitor in multiple myeloma. "This appointment comes at a pivotal time for Remedy Plan, as we finalize our IND-enabling studies for our hyperbolic NAMPT inhibitor, RPT1G," said Greg Crimmins, Ph.D., CEO and Founder of Remedy Plan Therapeutics. "We are thrilled to welcome Dr. Choe-Juliak to the team. Her extensive background in oncology clinical development and proven track record in advancing therapeutics to the clinic will be important as we begin our clinical program." "Remedy Plan's unique approach is the first that enables the partial inhibition of NAMPT. This allows for cancer cell growth inhibition without the on-target toxicities that have been seen with other NAMPT inhibitors," said Dr. Choe-Juliak. "I am inspired by the pioneering research and excited to help bring RPT1G to patients." Alongside the expansion of its leadership team, Remedy Plan also announced the expansion of its board of directors with the addition of Christian Waage, JD as an Independent Director. Mr. Waage is a biotech executive with more than two decades of experience in the industry. He is currently EVP, Technical Operations and Administration at Gossamer Bio Inc. and has previously held executive positions at Ardea Biosciences, Inc., Receptos Inc. and Celgene Corporation. About Remedy Plan Therapeutics Remedy Plan is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for allosteric inhibition of NAMPT that is fractional and highly tunable. NAMPT is an enzyme that controls how cells use energy and is core to human biology. NAMPT dysregulation is responsible for more than 20 diseases. Efforts to reduce NAMPT activity to date have resulted in unmanageable toxicities to healthy cells due to the dual role of NAMPT in healthy cell functioning and disease. Remedy Plan's groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. Remedy Plan is advancing a robust pipeline of tunable NAMPT inhibitors to address NAMPT dysregulation in solid tumors, hematologic malignancies, obesity, and autoimmune disorders. About RPT1G, a novel oncology therapeutic Remedy Plan's lead asset is RPT1G, a clinical drug candidate for the treatment of hematological malignancies. RPT1G has a unique, first-in-class mechanism of action that is optimized to preserve the cellular metabolism in healthy cells, while inhibiting activity in malignant cells. With a favorable efficacy and tolerability pro animals, RPT1G will be advancing to the clinic in 2024. For more information, please visit and follow Remedy Plan on social media: Contact: Parisa Moghaddam-Taaheri, Ph.D. parisa@remedyplan.com, (240) 408-4854 SOURCE: Remedy Plan Therapeutics View source version on accesswire.com:

David Berry joined Flagship as a Harvard and MIT wunderkind in 2005 and by now he’s been at the firm almost as long as anyone not named Noubar. He’s played a hand in some of their biggest startups, including Seres, Omega, KSQ, Evelo and, of course, Moderna. Flagship is known for its flash, but over the last couple years, Berry has been quietly building a computational startup in Boston that he thinks can remake drug development in a way that, for all the buzz, machine learning and artificial intelligence have yet to do. He’s managed to convince at least a few investors of that vision, raising $100 million in a Series A, $50 million in an undisclosed financing and a $190 million in a Series B despite remaining far from the clinic. On Tuesday, Valo revealed another investor who bought in, adding $110 million from Koch Disruptive Technology, the venture capital arm of the famed and infamous holding company Koch Industries. Koch Disruptive Technologies has invested in a broad swatch of tech companies but not yet waded deeply into biotech. In backing Valo, they are buying into what Berry says is a new way of thinking about drugs and tech and data. “As we look at the process that exists in drug development or drug discovery today, it’s effectively a point-to-point process and each of the steps has its own data, its own way of making decisions,” Berry told Endpoints News. “As the drug moves through its various steps, it’s as if it’s been thrown over a wall.” AI and machine learning have largely been deployed at individual steps of the drug development process: used by Atomwise, for example, to screen massive libraries for the best molecule, or by Insitro to find the difference between diseased and healthy cells, and the places where developers might be able to intervene and turn one to the other. Separately, large pharmas and small biotechs like BlackThorn have used machine learning to design trials and find the best patients. Berry argues that we need a better system — a better platform — that can integrate all those various sources and applications of data from the outset, allowing companies to overcome the hurdles that tend to appear as a drug goes through development. And that data should be grounded in humans (as opposed to mice or monkey experiments) to increase the odds that basic lab insights actually translate into the clinic. With about 110 employees, large amounts of human data, including what they claim is the “largest and most-detailed cardio-metabolic dataset in the world,” and reams and reams of cloud space, they’ve built a platform they call Opal to do that. For example, Berry claimed, they’ve developed an algorithm that allows them to predict the toxicology of any given compound with 86% accuracy. They also use 3D physics software to simulate and design molecules, adopting a similar approach to the well-partnered computational biotech Schrödinger, which has long argued that the AI algorithms many startups use to screen for molecules struggle because they rely on 2D images of 3D molecules. “When you ask the computer to try learn that a 2d image represents a 3D structure — that’s a very hard thing for a computer to learn,” Berry said. To find new targets, the platform and Valo’s scientists combine “omics” data – genomics, proteomics, even the much less talked about metabolomics — with data that track how patients change as they age and their diseases progress or wane. “Diseases are dynamic,” he said. Valo will use the new proceeds to continue hiring a few dozen more employees and progress the platform. With two years of runway, it will also give them the cash to get into the clinic, Berry said. Although they haven’t gone deep into details, Valo did release their first batch of cancer targets earlier this year: NAMPT, PARP1, USP28 and HDAC3. Their targets for neurodegeneration and cardiovascular disease remain undisclosed.